NCT04616560 2026-03-19
Trastuzumab Deruxtecan for the Treatment of HER2+ Newly Diagnosed or Recurrent Osteosarcoma
National Cancer Institute (NCI)
Phase 2 Suspended
Clinical Trials
12 trialsNCT05554380 2026-03-19
Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment Trial
National Cancer Institute (NCI)
Phase 2 Suspended
NCT05797870 2026-03-19
Lip-Re2
Center Eugene Marquis
Phase 2 Suspended
NCT05223036 2026-03-18
Testing Obeticholic Acid for Familial Adenomatous Polyposis
National Cancer Institute (NCI)
Phase 2 Suspended
NCT07283705 2026-03-18
A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer
M.D. Anderson Cancer Center
Phase 2 Suspended
NCT05656131 2026-03-17
Fluzoparib in Combination With or Without Camrelizumab for Homologous Recombinant Deficiency (HRD) HER2 Negative Advanced Breast Cancer
Sun Yat-sen University
Phase 2 Suspended
NCT05903092 2026-03-12
MOZART
Hoosier Cancer Research Network
Phase 2 Suspended
NCT07011550 2026-03-11
Phase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine/Tipiracil and Bevacizumab for Patients Refractory to Standard of Care Treatment and With Microsatellite-stable Colorectal Cancer
M.D. Anderson Cancer Center
Phase 2 Suspended
NCT06385262 2026-03-06
TOP 2301: Neoadjuvant Chemo for NSCLC
Duke University
Phase 2 Suspended
NCT06860386 2026-03-06
Study of Adaptive Immunotherapy With VEGFR-TKI in Patients With Advanced RCC
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Suspended
NCT03994796 2026-03-04
Genetic Testing in Guiding Treatment for Patients With Brain Metastases
Alliance for Clinical Trials in Oncology
Phase 2 Suspended
NCT05960773 2026-03-04
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma
National Institutes of Health Clinical Center (CC)
Phase 2 Suspended